Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Platform
  • Pipeline
  • Patients
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
    • Job Openings
  • Contact
May 25, 2021 8:00am EDT

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech

May 20, 2021 8:00am EDT

Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

May 17, 2021 7:00am EDT

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 10, 2021 8:00am EDT

Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021

Apr 26, 2021 8:00am EDT

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Apr 10, 2021 2:15pm EDT

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

Mar 30, 2021 7:00am EDT

Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update

Mar 25, 2021 8:00am EDT

Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA® (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen

Mar 23, 2021 8:00am EDT

Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021

Feb 23, 2021 8:00am EST

Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • Next
RSS
© 2023 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences